Trial Profile
A 14 Week Randomized Parallel Group Placebo-Controlled Double-Blind Multicentre Study Of Fesoterodine 8 Mg In Overactive Bladder Patients With Sub-Optimal Response To Tolterodine 4 Mg Extended Release (ER).
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 12 Dec 2018
Price :
$35
*
At a glance
- Drugs Fesoterodine (Primary) ; Tolterodine
- Indications Overactive bladder
- Focus Therapeutic Use
- Acronyms AFTER
- Sponsors Pfizer
- 31 Aug 2018 Results (n=6689) of pooled analysis from 6 studies (A0221008, A0221012, A0221013, A0221046, A0221094, A0221095) characterising patient symptom response resented at the 48th Annual Meeting of the International Continence Society
- 31 Aug 2018 Results (n=6689) of pooled analysis from 6 studies (A0221008, A0221012, A0221013, A0221046, A0221094, A0221095) examining efficacy and safety presented at the 48th Annual Meeting of the International Continence Society
- 31 Aug 2018 Results (n=6689) of pooled analysis from 6 studies (A0221008, A0221012, A0221013, A0221046, A0221094, A0221095) examing the relationship between disease variable resolution end of 4, 8 or 12 weeks treatment with fesoterodine and the proportion of patients achieving a significant improvement in Patient Reported Outcome Measures (PROM) resented at the 48th Annual Meeting of the International Continence Society